Thanks for adding that extra info Marion, much appreciated!

Not specifically CC related but very interesting I thought though.

Precision medicine trial first of its kind to show benefit to patients

http://www.cancerresearchuk.org/about-u … o-patients

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

http://www.ncbi.nlm.nih.gov/pubmed/27658789

Cholangiocarcinoma, gone without the Wnt?

http://www.ncbi.nlm.nih.gov/pubmed/27660676

Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah.

"CONCLUSIONS:
Relatives of BTC patients are not at an increased risk of GBC or CC in a statewide population. This suggests that biliary tract cancer risk is not associated with a familial predisposition and may be mitigated more strongly by environmental modifiers."

http://www.ncbi.nlm.nih.gov/pubmed/27655103

Cystic and Papillary Neoplasm at the Hepatic Hilum Possibly Originating in the Peribiliary Glands.

http://www.ncbi.nlm.nih.gov/pubmed/27656307

Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival.

http://www.ncbi.nlm.nih.gov/pubmed/27654107

Performance of bile aspiration plus brushing to diagnose malignant biliary strictures during endoscopic retrograde cholangiopancreatography.

http://www.ncbi.nlm.nih.gov/pubmed/27651736

Detection of Primary Malignancy and Metastases with FDG PET/CT in Patients with Cholangiocarcinomas: Lesion-based Comparison with Contrast Enhanced CT.

http://www.ncbi.nlm.nih.gov/pubmed/27651736

Modifying Health Behavior for Liver Fluke and Cholangiocarcinoma Prevention with the Health Belief Model and Social Support Theory.

http://www.ncbi.nlm.nih.gov/pubmed/27644606

Association between Pesticide Use and Cholangiocarcinoma.

http://www.ncbi.nlm.nih.gov/pubmed/27644648

Factors Associated with Periductal Fibrosis Diagnosed by Ultrasonography Screening among a High Risk Population for Cholangiocarcinoma in Northeast Thailand.

http://www.ncbi.nlm.nih.gov/pubmed/27644673

Plasma Lipidomics as a Tool for Diagnosis of Extrahepatic Cholangiocarcinoma in Biliary Strictures: a Pilot Study.

http://www.ncbi.nlm.nih.gov/pubmed/27644677

Thanks for that Marion.

2016 Research Fellowship Award - Our Press Release.

Scientists Investigate Improved Treatments and a Cure for Rare Disease – Bile Duct Cancer

Now Accepting Applications for the Cholangiocarcinoma Foundation Research Fellowship Program

CCF values open-access research by early career investigators that involves and catalyzes collaboration.— Stacie Lindsey, CCF President and FounderSALT LAKE CITY, UTAH, UNITED STATES, September 16, 2016 /EINPresswire.com/ -- The Cholangiocarcinoma Foundation (CCF), a nonprofit organization funding novel research for bile duct cancer is now accepting applications for the 3rd cycle of its Research Fellowship Program.

Since 2015, the Foundation has awarded 4 grants totaling $200,000 to outstanding scientists to raise awareness about cholangiocarcinoma and inspire innovative, quality research. Our funding supports research that opens new pathways for diagnosis and drug discovery thereby accelerating a path to a cure.

Applications are accepted from not-for-profit academic, medical or research institutions worldwide. We support high quality projects proposed by early career investigators who have a demonstrated commitment to cholangiocarcinoma research. Post-doctoral Fellows and Instructors with the following degrees are eligible to apply: MD, PhD, PharmD, or DVM. There are no restrictions for applicants as to age or national origin.

The “Impact Award” will fund up to $50,000. New for 2017 is the “Collaboration Award” that will fund studies up to $100,000 and requires multi-institutional collaboration. The deadline to apply is October 1, 2016.

“Through these studies, CCF’s Research Fellowship Program aims to gain insights and achieve significant milestones into the research of cholangiocarcinoma” said Donna Mayer, Executive Director of the Cholangiocarcinoma Foundation. “We are proud to honor and support remarkable scientists as they carry on the legacies of those for whom the grants are named.”


The 2016 recipients are:


Andrea Marie Fuquay Memorial Research Fellowship
2-HG as a Biomarker in Patients with IDH-mutant Intrahepatic Cholangiocarcinoma
Amount: $50,000
Researcher: Lipika Goyal, MD - Massachusetts General Hospital

Andrea Scott Memorial Research Fellowship
A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma Amount: $50,000
Researcher: Sumera Rizvi, MD - Mayo Clinic

Christopher J. Wilke Memorial Research Fellowship
Metabolic Reprogramming by IDH Mutation in Cholangiocarcinoma
Amount: $50,000
Researcher: Lei Shi, Ph.D - Massachusetts General Hospital


Innovation Award
Contribution of Hepatic Stellate Cells to Intrahepatic Cholangiocarcinoma
Amount: $50,000
Researcher: Silvia Affo, PhD - Columbia University


About Cholangiocarcinoma
Cholangiocarcinoma, a highly lethal cancer with poor prognosis, arises from the bile ducts in the liver. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the imminent need for novel therapies.

There are no effective strategies for prevention, early diagnosis or long-term treatment, indicating a significant unmet medical need. The risk factors and genetic causes of CC are not well known and clinical treatment options are extremely limited. Even with aggressive treatment, survival rates are low and average survival is only 6 month from diagnosis.

Although considered rare, with 5,000-6,000 cases a year being diagnosed in the US, the worldwide incidence and mortality is increasing thus research into this deadly disease is urgently needed.

About the Cholangiocarcinoma Foundation   
Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer through advocacy, education, collaboration and research.

APPLY NOW for a Research Fellowship Grant.
Donna Mayer
Cholangiocarcinoma Foundation
2153756362

http://www.einnews.com/pr_news/34512193 … uct-cancer

2016 Blue Ribbon Panel, 10 research recommendations.

Just seen this today -

https://www.cancer.gov/research/key-ini … bbon-panel

A lot of stuff on twitter right now about the Jo Biden speech and no doubt a lot of news reports as well will follow his speech.

Google has a few right now that are worth reading but we can't link them here for copyright reasons. Go to google, search cancer moonshot, serach by latest news and you will see the latest links.

#cancermoonshot is trending right now on twitter for those on twitter as well.

Hugs to all,

Gavin

That is a great idea Ben, good luck with it all and please let us all know how it goes.

Best wishes,

Gavin

Thanks for all of that Anne, very useful indeed. And please, no apologies for your English it sounded perfect to me and is better than mine!!!

My best to you and your husband,

Gavin

### Sensitive ###

Terminal cancer patients 'not getting adequate pain relief'

https://www.leeds.ac.uk/news/article/39 … ain_relief

This piece in a UK newspaper on the back of the above study also from this week -

Cancer patients not given painkillers soon enough, study finds

https://www.theguardian.com/society/201 … -gps-study

Reason I marked these pieces as sensitive as it does discuss pain etc for patients and some people may find this a sensitive issue to read about.

Pain is something that can be controlled and it is something that should be discussed and looked into if it is an issue. If something does not work then do not take no for an answer and look for something else to try.

Hugs,

Gavin

Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis and Stent Dysfunction after Preoperative Biliary Drainage in Patients with Malignant Biliary Stricture.

http://www.ncbi.nlm.nih.gov/pubmed/27629944

Thanks for this Marion!

Thanks for this Marion, looking forward to reading all the stories from everyone! And hoping to read a LOT of them over time!!

Hugs to all,

Gavin

Intrahepatic cholangiocarcinoma coinciding with a liver metastasis from a rectal carcinoma: a case report.

http://www.ncbi.nlm.nih.gov/pubmed/27612869

Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.

http://www.ncbi.nlm.nih.gov/pubmed/27599527

Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells.

http://www.ncbi.nlm.nih.gov/pubmed/27601921